Comparing Revenue Performance: Bausch Health Companies Inc. or Dynavax Technologies Corporation?

Bausch vs. Dynavax: A Decade of Revenue Dynamics

__timestampBausch Health Companies Inc.Dynavax Technologies Corporation
Wednesday, January 1, 2014826350000011032000
Thursday, January 1, 2015104988000004050000
Friday, January 1, 2016967400000011043000
Sunday, January 1, 20178724000000327000
Monday, January 1, 201883800000008198000
Tuesday, January 1, 2019860100000035219000
Wednesday, January 1, 2020802700000046551000
Friday, January 1, 20218434000000439442000
Saturday, January 1, 20228124000000722683000
Sunday, January 1, 20238757000000232284000
Loading chart...

Unlocking the unknown

Revenue Performance: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, revenue growth is a key indicator of success. Bausch Health Companies Inc. and Dynavax Technologies Corporation, two prominent players, have shown contrasting revenue trajectories from 2014 to 2023.

Bausch Health Companies Inc.

Bausch Health has consistently maintained a robust revenue stream, averaging around $8.75 billion annually. Despite a slight dip in 2020, the company rebounded with a 9% increase by 2023, showcasing resilience and strategic market positioning.

Dynavax Technologies Corporation

In contrast, Dynavax's revenue journey is marked by volatility. Starting with modest figures in 2014, the company experienced a significant surge in 2021, with revenues increasing by over 3,800% compared to 2014. However, 2023 saw a decline, indicating potential market challenges.

This comparison highlights the diverse strategies and market dynamics influencing revenue performance in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025